Nestlé Divests Palforzia Business

Peanut allergy treatment business divested to Stallergenes Greer.

Powder Bulk Solids Staff

September 5, 2023

1 Min Read
Nestlé logo
Nestlé has divested Palforzia, its peanut allergy treatment business, to Stallergenes Greer.Image courtesy of Nestlé

Nestlé has divested Palforzia, its peanut allergy treatment business, to Stallergenes Greer, a biopharmaceutical company that specializes in the diagnosis and treatment of allergies. The transaction was closed upon signing.

This agreement follows Nestlé's announcement last year that it would conduct a strategic review of Palforzia. Nestlé will receive milestone payments and ongoing royalties from Stallergenes Greer.

"We are confident that Stallergenes Greer will take Palforzia forward and ensure this unique treatment supports patients around the world," said Greg Behar, CEO of Nestlé Health Science. "At the same time, the divestiture allows Nestlé Health Science to focus on its core strengths and key growth drivers."

A transition period will ensure business continuity and provide patients uninterrupted access to the treatment.

About the Author

Powder Bulk Solids Staff

Established in 1983, Powder & Bulk Solids (PBS) serves industries that process, handle, and package dry particulate matter, including the food, chemical, and pharmaceutical markets.

Sign up for the Powder & Bulk Solids Weekly newsletter.

You May Also Like